Conclusion
In summary, precision medicine has helped with better understanding of
the biology and oncogenic mechanisms of lung cancer. This has led to a
new foundation of rationally designed therapeutic regimens including
targeted and immunotherapy, thus expanding the therapeutic landscape of
lung cancer. These regimens have high efficacy and manageable toxicity
profiles, which in turn has led to improved survival. With these new
advancements, we are touching new horizons in lung cancer treatment and
in near future it is expected that chemotherapy will not be commonly
used and lung cancer patients will have longer and better quality of
life.